Adrian Dascalu Email & Phone Number

Bethesda, Md

Uppsala, Sweden

 Evaluated the effects of novel HSP90 inhibitor on colorectal and oral squamous cell carcinoma cell lines in conjunction with various gamma irradiation regiments Characterized the impact of novel HSP90 inhibitor on cancer cell survivability, radiosensitivity, DNA damage repair efficiency, cell cycle progression and protein expression Assessed the potential clinical application of the novel HSP90 inhibitor for anti-cancer therapy  Quantified cell surface receptors and conducted a ligand binding kinetics analysis using a Ridgeview Ligand Tracer Grey instrument Explored the ability of an EGFR inhibitor and cell starvation to modify receptor ligand binding and dimerization interactions Demonstrated qualities of experimental awareness and ability to extrapolate needs for further testing based on current findingsSubmission for Publication- Journal of Molecular Cancer Therapeutics (2014)The novel Hsp90 inhibitor AT13387 potentiates the radiation effect of squamous cell carcinoma and adenocarcinoma cells Diana Spiegelberg, Adrian Dascalu, Gamze Kuku, Bo StenerlöwSubmission for Publication- Journal of Pharmacological and Toxicological Methods (2014) Determination of Receptor Protein Binding Site Specificity and Relative Binding Strength Using a Time Resolved Competition Assay Pavel Barta, Marie Volkova, Adrian Dascalu, Diana Spiegelberg, Frantisek Trejtnar, Karl Andersson

 Conducted PCR-based genotyping of breast cancer patients to correlate cancer risk with breast density and various single-nucleotide polymorphism (SNP) alleles Tasked with use and update of patient blood sample database

 Organized and collated data from 2-dimensional gel electrophoresis runs

Bachelor'S Of Science, Biology

 Major GPA: 3.43  Honors: Dean’s List  Successfully bred and isolated D. melanogaster phenotypes displaying knockdown of dusky-like.

Master'S Of Science, Molecular Cell Biology

 (Thesis): Characterizing the Effects of a Novel HSP90 Inhibitor on Colorectal Adenocarcinoma and Oral Squamous Cell Carcinoma.